Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;312(1):R5-R12.
doi: 10.1152/ajpregu.00440.2016. Epub 2016 Nov 30.

Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia

Affiliations
Review

Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia

Frank T Spradley. Am J Physiol Regul Integr Comp Physiol. .

Abstract

Preeclampsia (PE), a hypertensive disorder of pregnancy, is increasing as a major contributor to perinatal and long-term morbidity of mother and offspring. PE is thought to originate from ischemic insults in the placenta driving the release of prohypertensive anti-angiogenic [soluble fms-like tyrosine kinase-1 (sFlt-1)] and proinflammatory [tumor necrosis factor-α (TNF-α)] factors into the maternal circulation. Whereas the increased incidence of PE is hypothesized to be largely due to the obesity pandemic, the mechanisms whereby obesity increases this risk are unknown. The maternal endothelium is targeted by placental and adipose tissue-derived factors like sFlt-1 and TNF-α that promote hypertension during pregnancy, resulting in vascular dysfunction and hypertension. Interestingly, not all obese pregnant women develop PE. Data suggest that obese pregnant women with the greatest metabolic abnormalities have the highest incidence of PE. Identifying obesity-related mechanisms driving hypertension in some obese pregnant women and pathways that protect normotensive obese pregnant women, may uncover novel protocols to treat PE. Metabolic abnormalities, such as increased circulating leptin, glucose, insulin, and lipids, are likely to increase the risk for PE in obese women. It is not only important to understand whether each of these metabolic factors contribute to the increased risk for PE in obesity, but also their cumulative effects. This is particularly relevant to obese pregnant women with gestational diabetes mellitus (GDM) where all of these factors are increased and the risk for PE is highest. It is speculated that these factors potentiate the anti-angiogenic and proinflammatory mechanisms of placental ischemia-induced vascular dysfunction thereby contributing to the increasing incidence of PE.

Keywords: adipose tissue; endothelium; gestational diabetes mellitus; hypertension; women’s health.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Hypothetical scheme with asterisks denoting where obesity and obesity-related abnormalities, such as increased leptin, glucose, insulin, and lipids, and gestational diabetes mellitus (GDM), may promote and even exaggerate the pathways linking placental ischemia to maternal hypertension.

References

    1. Aasa KL, Zavan B, Luna RL, Wong PG, Ventura NM, Tse MY, Carmeliet P, Adams MA, Pang SC, Croy BA. Placental growth factor influences maternal cardiovascular adaptation to pregnancy in mice. Biol Reprod 92: 44, 2015. doi:10.1095/biolreprod.114.124677. - DOI - PMC - PubMed
    1. Al-Badri MR, Zantout MS, Azar ST. The role of adipokines in gestational diabetes mellitus. Ther Adv Endocrinol Metab 6: 103–108, 2015. doi:10.1177/2042018815577039. - DOI - PMC - PubMed
    1. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy . Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122: 1122–1131, 2013. doi:10.1097/01.AOG.0000437382.03963.88. - DOI - PubMed
    1. Avagliano L, Marconi AM, Romagnoli S, Bulfamante GP. Abnormal spiral arteries modification in stillbirths: the role of maternal prepregnancy body mass index. J Matern Fetal Neonatal Med 25: 2789–2792, 2012. doi:10.3109/14767058.2012.705395. - DOI - PubMed
    1. Aye IL, Rosario FJ, Powell TL, Jansson T. Adiponectin supplementation in pregnant mice prevents the adverse effects of maternal obesity on placental function and fetal growth. Proc Natl Acad Sci U S A 112: 12858–12863, 2015. doi:10.1073/pnas.1515484112. - DOI - PMC - PubMed

LinkOut - more resources